Drugs.com - Pharma Industry News

Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes

FRIDAY, June 20, 2025 -- For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and cardiovascular event risks, according to a study published online June 17 in...

Jun 20, 2025 - 19:00
 0
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
FRIDAY, June 20, 2025 -- For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and cardiovascular event risks, according to a study published online June 17 in...
Read More

Tags:

Previous Article

Nearly Half With Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five ...

Next Article

Racial, Ethnic Differences Seen in Teens' Use of Mental Health Services

Related Posts

Some Triple Negative Breast Cancers Might Be Avoided by Longer Breastfeeding

Some Triple Negative Breast Cancers Might Be Avoided by...

May 15, 2025  0

In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity

In Pediatric Leukemia, Survival Linked to Duration of O...

May 20, 2025  0

Pediatric Skin Care Regimens on TikTok Offer Few Benefits, Possible Harm

Pediatric Skin Care Regimens on TikTok Offer Few Benefi...

Jun 11, 2025  0